dr. geyer on impact of targeted agents in her2 breast cancer
Published 5 years ago • 120 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
0:52
dr. o'regan on impact of targeted agents in her2 breast cancer
-
1:52
dr. geyer discusses pertuzumab in her2 breast cancer
-
2:05
dr. geyer discusses challenges in her2-positive metastatic breast cancer management
-
1:31
dr. geyer on the rationale for the katherine trial in her2-positive breast cancer
-
1:19
dr. pegram discusses the use of neratinib in her2 breast cancer
-
1:37
dr. bhave on promising anti-her2 agents in her2 breast cancer
-
2:18
dr. hershman on the use of endocrine therapy in premenopausal hr /her2- breast cancer
-
1:50
dr lynce on ongoing trials evaluating novel combinations in inflammatory breast cancer
-
2:30
dr. pegram on neoadjuvant treatments for her2-postive breast cancer
-
0:57
dr. marks on the role of tkis in her2-positive breast cancer
-
1:33
dr. rimawi on the clinical need for immunotherapy in her2-positive breast cancer
-
1:51
dr. kolberg on cost-effectiveness of pertuzumab in her2-positive breast cancer
-
1:24
dr. yardley on emerging agents in her2-positive breast cancer
-
0:57
dr. mittendorf on the impact of pertuzumab in her2 breast cancer
-
0:59
sequencing her2-targeted therapies in breast cancer
-
1:31
dr. gwin on the mechanism of action of 𝞪-tea in her2-positive metastatic breast cancer
-
2:01
dr. hurvitz on her2-targeted therapies in breast cancer
-
0:52
dr. swain on the impact of chemotherapy on outcomes in her2-positive metastatic breast cancer
-
0:52
dr. graff on future research with immunotherapy in breast cancer